产品说明书

Decoquinate

Print
Chemical Structure| 18507-89-6 同义名 : -
CAS号 : 18507-89-6
货号 : A205365
分子式 : C24H35NO5
纯度 : 98%
分子量 : 417.538
MDL号 : MFCD00673686
存储条件:

粉末 Inert atmosphere,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 : -
动物实验配方:
生物活性
描述 Decoquinate is a quinolone anticoccidial approved for use in the prevention of intestinal coccidiosis in farm animals. This compound has good activity against Toxoplasma gondii and Neospora caninum in cell cultures. The drug acts on the parasites' mitochondria. Merozoite production at 10 days was completely inhibited when decoquinate was used at 20 or 240 nM. The IC50 of decoquinate was 0.5 ± 0.09 nM for the Sn6 isolate of S. neurona from a horse and 1.1 ± 0.6 nM for the SnOP15 isolate of S. neurona from an opossum. Decoquinate was cidal for developing schizonts of S. neurona at 240 nM[3]. Decoquinate treats coccidiosis in lambs and calves and prevents coccidiosis in lambs when administered in feed at a dosage of 1 mg decoquinate/kg bodyweight (b.w.) daily for at least 28 days[4]. Oral administration of nanoparticle decoquinate at a dose of 1.25 mg/kg effectively inhibited the liver-stage parasite growth and provided complete causal prophylactic protection. This efficacy is 15 fold greater than that observed for microparticle decoquinate, which requires minimal dose of 20 mg/kg for the same inhibitory effect[5]. Sheep were given decoquinate in their feed daily at either 2 mg or 1 mg/kg bodyweight from 10 days before an oral challenge with Toxoplasma gondii oocysts at 90 days of gestation, until lambing. Feeding decoquinate at the higher rate caused a delay in the onset of the febrile response to infection, reduced the overall severity of the fever and delayed the production of antibodies to the parasite. This treatment also reduced the placental damage caused by the parasite, lengthened the mean gestation period and increased the number and weight of live lambs, in comparison with ewes not fed decoquinate but challenged with T gondii oocysts[6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.97mL

2.39mL

1.20mL

23.95mL

4.79mL

2.39mL

参考文献

[1]Moore DA, Atwill ER, et al. Prophylactic use of decoquinate for infections with Cryptosporidium parvum in experimentally challenged neonatal calves. J Am Vet Med Assoc. 2003 Sep 15;223(6):839-45.

[2]Lindsay DS, Toivio-Kinnucan MA, Blagburn BL. Decoquinate induces tissue cyst formation by the RH strain of Toxoplasma gondii. Vet Parasitol. 1998 Jun 15;77(2-3):75-81.

[3]Lindsay DS, Nazir MM, Maqbool A, Ellison SP, Strobl JS. Efficacy of decoquinate against Sarcocystis neurona in cell cultures. Vet Parasitol. 2013;196(1-2):21‐23

[4]Taylor MA, Bartram DJ. The history of decoquinate in the control of coccidial infections in ruminants. J Vet Pharmacol Ther. 2012;35(5):417‐427

[5]Wang H, Li Q, Reyes S, et al. Nanoparticle formulations of decoquinate increase antimalarial efficacy against liver stage Plasmodium infections in mice. Nanomedicine. 2014;10(1):57‐65

[6]Buxton D, Brebner J, Wright S, Maley SW, Thomson KM, Millard K. Decoquinate and the control of experimental ovine toxoplasmosis. Vet Rec. 1996;138(18):434‐436